AI’s Real-World Impact on Biotech and Clinical Research in 2025
As we navigate through 2025, AI is beginning to impact the world of biotech and clinical research, though the narrative is more nuanced than early hype suggested. From drug discovery to trial optimization, AI is advancing, yet challenges remain in its practical application.
1. Drug Discovery: Real Acceleration Amid Early Caution
AI-backed startups are leading the charge in drug discovery. Chai Discovery, supported by OpenAI, recently raised $70 million, achieving a valuation around $550 million. Its latest AI model, Chai‑2, demonstrated a hit rate of one in six proteins bound successfully, versus the traditional one in 1,000. This is demonstrating big business’ belief in AI’s potential to accelerate drug design. However, no AI-discovered drug has received regulatory approval yet.
Meanwhile, Isomorphic Labs, spun out of DeepMind, secured $600 million in early 2025. The company builds on AlphaFold’s protein folding success and seeks to scale AI-powered drug design.
2. Biotech Innovation Through AI-Powered Development
Independent biotech firms are benefiting from AI innovation. SOM Biotech in Spain uses its AI-based SOMAI PRO platform to identify orphan disease therapies, streamlining identification of mechanisms of action and reducing R&D costs.
French AI-biotech Owkin leverages federated learning to train models across hospital networks privately. Its tools assist in drug discovery, diagnostics, and clinical trial optimization, backed by collaborations with major pharma partners.
Generate:Biomedicines brought AI into mainstream pharma territory by raising substantial funds and signing a $1 billion-plus partnership with Novartis to develop protein therapeutics via its generative AI platform.
3. Optimizing Clinical Trials with AI
AI is reshaping how trials are designed and conducted. The TrialMatchAI system, introduced in May 2025, uses large language models to match patients with relevant oncology trials, achieving over 90% accuracy and delivering the right matches for 92% of patients in top recommendations.
At the DIA Global Annual Meeting 2025, industry leaders spotlighted advanced AI tools—such as digital twins, generative AI for synthetic data, and real-time analytics—to enhance trial design and execution.
4. Operational and Workforce Transformation
Major pharma companies are not waiting. Firms like Johnson & Johnson, Merck, and Eli Lilly are upskilling their workforce in AI: J&J mandates generative AI training for tens of thousands of employees, Merck deployed GPTeal to secure usage of generative AI tools internally, and Eli Lilly requires AI certification for leadership roles. These efforts signal AI literacy becoming central to operational strategy.
5. Challenges and Cautious Optimism
Despite breakthroughs, leaders warn that AI’s promise must be tempered by real-world constraints. Experts noted that despite the early enthusiasm sparked by tools like AlphaFold, the broader application of AI across R&D still faces data fragmentation and regulatory hurdles.
“There’s no question AI has potential, but I’ve seen it oversold in clinical research. The safety of participants with novel drugs is absolutely paramount as the margin for error is razor-thin,” says Dinkar Sindhu, CEO of AXIS Clinicals. “What’s made the biggest difference in my experience isn’t technology for technology’s sake, it’s been doubling down on operational safety, real-time decision-making and strong site-lab integration. AI might eventually catch up, but for now, the gains are coming from systems that are proven, not promised.”
While AI investment continues to soar, the biotech/pharma AI market is projected to surge from roughly $1.94 billion in 2025 to $16.5 billion by 2034. Industry transformation will require consistent, validated performance, not just hype.
Conclusion
In 2025, AI has transitioned from speculative trend to an increasingly embedded strategic asset in biotech and clinical research. From breakthrough startups and AI-first drug design platforms to precision diagnostics and trial matching, genuine progress is visible, but tempered by the need for validation and integration.